Keywords: sonus, tocosol, misses, ph, iii, endpoint, drug

Sonus' Tocosol misses Ph III endpoint, drug's future uncertain

Article | 08 October 2007

Print This

Sonus Pharmaceuticals' Phase III pivotal trial of Tocosol Paclitaxel in women with metastatic breast cancer missed its primary endpoint of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in